Testing a Gene Therapy for Adults Whose High-Grade Glioma Has Come Back
Original title: A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people that is still checking safety and dose.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a new gene therapy in adults whose brain cancer has returned.
Who this trial is for. This trial is for adults whose high-grade glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary came back for the first time. It is for people who are not planned to have surgery on the tumor. It tests a gene therapy called SRN-101, given as one infusion into the tumor.
Where it stands. This trial has not reported results. It is checking how safe SRN-101 is. It is also looking for early signs that it acts against the tumor. The team will look at different dose levels first. Then they will study one chosen dose in more people. Taking part means MRI scans, blood tests, and follow-up visits. The answers are not in yet.
What this means, and what it doesn't
What it could mean: Someone who fits this picture could ask their care team about it. The care team can say whether a study like this makes sense. The therapy is put into the tumor during an MRI-guided procedure, so this is a big step to think through.
What it doesn't mean: This does not mean SRN-101 works. The source says its safety and effectiveness have not been established. A trial is a test, not a proven treatment. Joining one is not a guarantee of any benefit. It is not a promise of a cure.
Source: ClinicalTrials.gov, October 28, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.